lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
UCB, INC.
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
March 27, 2026
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
March 27, 2026
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
March 24, 2026
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
March 11, 2026